Evidence map›Paper›PMID 34628726›Full record

ArticleHepatology communications2022

Shelter-Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness.

Mandana Khalili, Jesse Powell, Helen H Park, Dylan Bush, Jessica Naugle, Margaret Ricco, Catherine Magee, Grace Braimoh, Barry Zevin, J Konadu Fokuo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mandana Khalili *Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9178-9139
Jesse Powell *Hennepin Healthcare, Minneapolis, MN, USA.
Helen H ParkDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1006-7028
Dylan BushDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Jessica NaugleSan Francisco Department of Public Health, Street Medicine and Shelter Health, San Francisco, CA, USA.
Margaret RiccoHennepin Healthcare, Minneapolis, MN, USA.
Catherine MageeDivision of Gastroenterology and Hepatology, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.
Grace BraimohHennepin Healthcare, Minneapolis, MN, USA.
Barry ZevinSan Francisco Department of Public Health, Street Medicine and Shelter Health, San Francisco, CA, USA.
J Konadu FokuoDepartment of Psychiatry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4299-689X
Carmen L MassonDepartment of Psychiatry, University of California San Francisco, San Francisco, CA, USA.
San Francisco General Hospital · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Substance Use Disorders Treatment/Services Research Training ProgramT32DA007250 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre, Janice Y Tsoh · 1991 to 2026
$7.4M
Mentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9M
NIAAA NIH HHS K24 AA022523NIDA NIH HHS T32 DA007250NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Hepatitis C virus (HCV) prevalence is high among people experiencing homelessness, but barriers to scaling up HCV testing and treatment persist. We aimed to implement onsite HCV testing and education and evaluate the effectiveness of low-barrier linkage to HCV therapy among individuals accessing homeless shelters. HCV rapid testing was performed at four large shelters in San Francisco (SF) and Minneapolis (MN). Sociodemographic status, HCV risk, barriers to testing, and interest in therapy were captured. Participants received information about HCV. Those testing positive underwent formal HCV education and onsite therapy. Multivariable modeling assessed predictors of receipt of HCV therapy and sustained virologic response (SVR). A total of 766 clients were tested. Median age was 53.7 years, 68.2% were male participants, 46.3% were Black, 27.5% were White, 13.2% were Hispanic, and 57.7% had high school education or less; 162 (21.1%) were HCV antibody positive, 107 (66.0%) had detectable HCV RNA (82.1% with active drug use, 53.8% history of psychiatric illness), 66 (61.7%) received HCV therapy, and 81.8% achieved SVR. On multivariate analysis, shelter location (MN vs. SF, odds ratio [OR], 0.3; P = 0.01) and having a health care provider (OR, 4.1; P = 0.02) were associated with receipt of therapy. On intention to treat analysis, the only predictor of SVR when adjusted for age, sex, and race was HCV medication adherence (OR, 14.5; P = 0.01). Conclusion: Leveraging existing homeless shelter infrastructure was successful in enhancing HCV testing and treatment uptake. Despite high rates of active substance use, psychiatric illness, and suboptimal adherence, over 80% achieved HCV cure. This highlights the critical importance of integrated models in HCV elimination efforts in people experiencing homelessness that can be applied to other shelter settings.

Indexed as

Ill-Housed PersonsAdultAgedAged, 80 and overFemaleHepacivirusHepatitis C, ChronicHumansMaleMiddle AgedMinnesotaPatient Education as TopicPrevalenceProspective StudiesRisk FactorsRNA, ViralRNA, Viral

Identifiers

PMID34628726
PMCPMC8710795
OpenAlexW3205712088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.